Vir Biotechnology, Inc. Investment Income, Interest
Vir Biotechnology, Inc. (VIR) reported Investment Income, Interest of $8.97 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-05
- Vir Biotechnology, Inc. investment income, interest for the quarter ending 2026-06-30 was $8.97M, a 16.87% decline year-over-year.
- Vir Biotechnology, Inc. investment income, interest for the quarter ending 2026-03-31 was $7.19M, a 41.50% decline year-over-year.
- Vir Biotechnology, Inc. investment income, interest for the quarter ending 2025-12-31 was $7.80M, a 44.87% decline year-over-year.
- Vir Biotechnology, Inc. investment income, interest for the quarter ending 2025-09-30 was $9.36M, a 46.58% decline year-over-year.
- Vir Biotechnology, Inc. investment income, interest for fiscal 2025 was $40.24M, a 43.97% decline from fiscal 2024.
- Vir Biotechnology, Inc. investment income, interest for fiscal 2024 was $71.81M, a 17.45% decline from fiscal 2023.
- Vir Biotechnology, Inc. investment income, interest for fiscal 2023 was $86.99M, a 209.66% increase from fiscal 2022.
- Vir Biotechnology, Inc. investment income, interest for fiscal 2022 was $28.09M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $8.97M 10-Q · filed 2026-08-05 | $16.16M 10-Q · filed 2026-08-05 | $23.96M derived: sum of 3 quarters · filed 2026-08-05 | $33.32M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $7.19M 10-Q · filed 2026-05-07 | $14.99M derived: sum of 2 quarters · filed 2026-05-07 | $24.35M derived: sum of 3 quarters · filed 2026-05-07 | $35.14M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $7.80M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $17.16M derived: sum of 2 quarters · filed 2026-02-23 | $27.95M derived: sum of 3 quarters · filed 2026-08-05 | $40.24M 10-K · filed 2026-02-23 |
| 2025-09-30 | $9.36M 10-Q · filed 2025-11-05 | $20.15M derived: sum of 2 quarters · filed 2026-08-05 | $32.44M 10-Q · filed 2025-11-05 | $46.59M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $10.79M 10-Q · filed 2026-08-05 | $23.07M 10-Q · filed 2026-08-05 | $37.23M derived: sum of 3 quarters · filed 2026-08-05 | $54.75M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $12.29M 10-Q · filed 2026-05-07 | $26.44M derived: sum of 2 quarters · filed 2026-05-07 | $43.97M derived: sum of 3 quarters · filed 2026-05-07 | $62.81M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $14.15M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $31.68M derived: sum of 2 quarters · filed 2026-02-23 | $50.53M derived: sum of 3 quarters · filed 2026-02-23 | $71.81M 10-K · filed 2026-02-23 |
| 2024-09-30 | $17.53M 10-Q · filed 2025-11-05 | $36.37M derived: sum of 2 quarters · filed 2025-11-05 | $57.66M 10-Q · filed 2025-11-05 | $78.39M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-06-30 | $18.85M 10-Q · filed 2025-08-06 | $40.13M 10-Q · filed 2025-08-06 | $60.87M derived: sum of 3 quarters · filed 2026-02-23 | $82.80M derived: sum of 4 quarters · filed 2026-02-23 |
| 2024-03-31 | $21.28M 10-Q · filed 2025-05-08 | $42.02M derived: sum of 2 quarters · filed 2026-02-23 | $63.95M derived: sum of 3 quarters · filed 2026-02-23 | |
| 2023-12-31 | $20.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-23 | $42.67M derived: sum of 2 quarters · filed 2026-02-23 | $86.99M 10-K · filed 2026-02-23 | |
| 2023-09-30 | $21.93M 10-Q · filed 2024-11-04 | $66.25M 10-Q · filed 2024-11-04 | ||
| 2022-12-31 | $28.09M 10-K · filed 2025-02-27 | |||
| 2020-09-30 | $412.00K 10-Q · filed 2020-11-10 | $1.24M derived: sum of 2 quarters · filed 2020-11-10 | $2.55M 10-Q · filed 2020-11-10 | $4.94M derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-06-30 | $825.00K 10-Q · filed 2020-08-11 | $2.58M 10-Q · filed 2020-08-11 | $4.53M derived: sum of 3 quarters · filed 2020-08-11 | $6.54M derived: sum of 4 quarters · filed 2020-11-10 |
| 2020-03-31 | $1.75M 10-Q · filed 2020-05-12 | $3.70M derived: sum of 2 quarters · filed 2020-05-12 | $5.71M derived: sum of 3 quarters · filed 2020-11-10 | $8.02M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-12-31 | $1.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $3.96M derived: sum of 2 quarters · filed 2020-11-10 | $6.27M derived: sum of 3 quarters · filed 2020-11-10 | $8.51M 10-K · filed 2020-03-26 |
| 2019-09-30 | $2.01M 10-Q · filed 2020-11-10 | $4.32M derived: sum of 2 quarters · filed 2020-11-10 | $6.56M 10-Q · filed 2020-11-10 | $7.18M derived: sum of 4 quarters · filed 2020-11-10 |
| 2019-06-30 | $2.31M 10-Q · filed 2020-08-11 | $4.55M 10-Q · filed 2020-08-11 | $5.17M derived: sum of 3 quarters · filed 2020-08-11 | $5.88M derived: sum of 4 quarters · filed 2020-08-11 |
| 2019-03-31 | $2.25M 10-Q · filed 2020-05-12 | $2.87M derived: sum of 2 quarters · filed 2020-05-12 | $3.58M derived: sum of 3 quarters · filed 2020-05-12 | |
| 2018-12-31 | $621.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | $1.33M derived: sum of 2 quarters · filed 2020-03-26 | $2.54M 10-K · filed 2020-03-26 | |
| 2018-09-30 | $712.00K 10-Q · filed 2019-11-19 | $1.92M 10-Q · filed 2019-11-19 | ||
| 2017-12-31 | $638.00K 10-K · filed 2020-03-26 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |